Your doctor has just suggested a new approach for depression that has not lifted. Maybe it is a medication you have never heard of, a nasal spray given at a clinic, or a magnetic stimulation treatment. You nod along. Then, on the drive home, a question you did not ask starts nagging at you: is this thing actually FDA-approved?

If that question matters to you, you have plenty of company. Our summer poll of 443 Midwest adults in ten states found 59 percent who would give FDA approval big or deciding weight before starting an unfamiliar depression treatment. This article gives you the words to ask about it in the room, not in the car afterward.

The poll numbers are final; Pollfish has validated them. None of it replaces your own clinician's advice.

Why it is worth asking directly

Most people cannot tell which depression treatments carry FDA approval, because most have never heard of the newer ones. Take Spravato, the esketamine spray approved for depression that has resisted treatment: our poll found 73 percent had never encountered the name, and a scant 6 percent could describe it.

Meanwhile, the word "ketamine" now covers several different things. One is approved for depression. Others are off-label uses. You cannot tell them apart from a headline, so asking is the only reliable way.

Before the appointment

Jot down two things. First, a list of the treatments you have already tried. Second, the questions you would most hate to leave without asking. If FDA status is at the top of your list, write it down so you do not lose it when the visit gets busy.

The core question

You can use this line as written:

"Before we decide, can you tell me whether this treatment is FDA-approved for my condition, and whether the way we'd be using it is on-label?"

It is a fair question, and a good doctor will not be offended by it. It gives your doctor a chance to explain the regulatory picture and why they are recommending this option.

Follow-ups depending on the answer

If the answer is "yes, it's FDA-approved":

"What does the approval cover exactly? Are there special safety requirements, like monitoring, that come with it?"

For esketamine, the answer involves a safety program. It is only given at certified healthcare sites, staff observe each patient for two hours or longer after every dose, and nobody drives home that day. Brain Recovery Centers has an overview of the Spravato treatment process you can read before the follow-up visit.

If the answer is "it's FDA-cleared":

"What does cleared mean compared with approved? What is the device cleared to treat?"

You will usually hear this about TMS, which uses a magnetic coil on the scalp instead of any medication. The FDA cleared its devices for adult major depression that antidepressants did not resolve, clearance being the route most devices take through FDA review.

If the answer is "it's off-label":

"What research backs this particular use? Why do you think it's a better choice for me than an approved option?"

Off-label prescribing is legal and common. IV ketamine for depression is an example. It is still worth understanding what evidence supports it and whether an approved alternative exists.

If it is a compounded or at-home product:

"Is this compounded? Who makes it, and how is it checked for quality? How is it different from the supervised version?"

Questions that go beyond the label

FDA status is one piece of the picture. These questions fill in the rest:

  • "Which side effects happen often, and which ones would be a real concern?"
  • "What will tell us it is working, and how many weeks do we wait to judge?"
  • "Is there anything in my history that makes this a poor fit?"
  • "Do I stay on my present prescription during the trial of this?"

On that last point, keep taking what you are on until your prescriber helps you plan a change. Stopping abruptly can cause problems.

Ask about cost in the same breath

For most respondents, coverage outweighed everything else. Picking only two provider priorities, 85 percent of respondents put insurance coverage on their list, while FDA approval drew just over a quarter, 27 percent, slightly ahead of fast results. Elsewhere in the questionnaire, coverage carried big or deciding weight for 65 percent.

So it makes sense to ask:

"Do you know whether my insurance covers this for depression? Will your office handle the prior authorization?"

Plans lean toward paying for approved and cleared treatments used as labeled, generally once prior authorization clears. Off-label and compounded options often are not.

Ask where it happens

Proximity ranked second in our survey, a priority for 43 percent of respondents. Supervised treatments require repeated visits. You can ask:

"Which site nearest me offers this, and how many trips a week would it take?"

If you run out of time

Appointments are short. If the conversation runs long, ask your doctor to jot the treatment's name on paper along with its status: approved, cleared, or off-label. Then you can look it up and follow up with a message or a second visit.

Your doctor is the best source here

Respondents trusted their doctors far more than anyone else on this question. Their doctor's recommendation would get 74 percent to try something new; an ad would sway 2 percent. And 56 percent said a primary care visit is where their search would begin. That trust is well placed. Your doctor can explain not just what a label says, but whether the treatment fits your history, which is the question that matters most.

Suicidal thoughts do not have to wait for a scheduled visit. The Suicide and Crisis Lifeline is one text or call away at 988, whatever the hour, with no appointment needed.

Methodology

Our figures come from Pollfish study 395586438, which drew people off Pollfish's consumer panel until collection stopped June 23, 2026. It holds 443 finished questionnaires, every respondent 18 to 64, from Wisconsin, Oklahoma, Iowa, Ohio, Kansas, Missouri, Nebraska, Minnesota, Illinois and Indiana, each screened for consent. Multi-select answers are percentages of everyone surveyed. Our numbers are the validated, final ones. The publisher commissioned the poll and paid its full cost.